Jauharatud Dini Suhaimi1, Nur Amanie Shafiee1, Jazli Sufri1, Haziq Momin1*
1. National Clinical Microbiology Reference Laboratory, Department of Laboratory Services, RIPAS Hospital, Ministry of Health, Brunei Darussalam
*Corresponding author: Dr Muhd Haziq Fikry Bin Haji Abdul Momin.
ABSTRACT
INTRODUCTION: The emergence of multidrug-resistant (MDR) Gram-negative bacteria, particularly those producing extended-spectrum beta-lactamases (ESBLs) and carbapenem-resistant Enterobacterales (CRE), poses a significant clinical challenge. Cefiderocol, a novel siderophore cephalosporin, utilises iron transport systems to penetrate bacterial cells and demonstrates potent activity against resistant pathogens.
OBJECTIVE(S): This study aimed to evaluate the in vitro susceptibility of Gram-negative clinical isolates to cefiderocol, with emphasis on ESBL- and CRE-producing strains, over a two-years (2023–2024).
MATERIALS & METHODS: A total of 8,491 Gram-negative isolates were recovered from clinical specimens (blood, urine, respiratory samples, and pus) and tested at the National Clinical Microbiology Reference Laboratory (NCMRL). Bacterial identification and antimicrobial susceptibility testing (AST) were performed using the Vitek 2XL automated system. Cefiderocol susceptibility testing was carried out using the Kirby-Bauer disk diffusion method and interpreted according to CLSI guidelines. The organisms included Acinetobacter baumannii, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens. Isolates were phenotypically classified as ESBL, CRE, or normal.
RESULTS: Of the 8,491 Gram-negative isolates tested over two years, 96.6% were sensitive to cefiderocol, 0.2% intermediate, and 0.3% resistant. A. baumannii, contributing the majority of resistant isolates (n=1,303), showed 96.8% sensitivity to cefiderocol. E. coli (n=1,523) and E. cloacae (n=430) showed near-complete or complete susceptibility. K. pneumoniae (n=1,314) and P. aeruginosa (n=1,252) also showed high sensitivity, with a few intermediate and resistant strains. All ESBL and CRE isolates demonstrated excellent susceptibility to cefiderocol. Resistance remained low across both years, though close monitoring is warranted for emerging intermediate trends in CRE strains.
CONCLUSION: Cefiderocol demonstrated excellent in vitro activity against a wide range of Gram-negative bacteria, including MDR organisms such as ESBL- and carbapenem-resistant strains. The consistently high susceptibility across two years, especially among CRE and ESBL isolates, supports the utility of cefiderocol as a potent therapeutic agent in settings with high antimicrobial resistance. Continuous surveillance and further clinical correlation are warranted to guide optimal use.
KEYWORDS: Cefiderocol, Multidrug-resistant Gram-negative Bacteria, Carbapenem-resistant Enterobacterales, Extended-spectrum Beta-lactamases, Antimicrobial Susceptibility Testing


